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Abstract
Introduction: Tuberculosis (TB) destroys lung tissues and this immunopathology is mediated in part by Matrix
Metalloproteinases (MMPs). There are no data on the relationship between local tissue MMPs concentrations, anti-
tuberculosis therapy and sputum conversion.
Materials and Methods: Induced sputum was collected from 68 TB patients and 69 controls in a cross-sectional study.
MMPs concentrations were measured by Luminex array, TIMP concentrations by ELISA and were correlated with a disease
severity score (TBscore). 46 TB patients were then studied longitudinally at the 2nd, 8th week and end of treatment.
Results: Sputum MMP-1,-2,-3,-8,-9 and TIMP-1 and -2 concentrations are increased in TB. Elevated MMP-1 and -3
concentrations are independently associated with higher TB severity scores (p,0.05). MMP-1, -3 and -8 concentrations
decreased rapidly during treatment (p,0.05) whilst there was a transient increase in TIMP-1/2 concentrations at week 2.
MMP-2, -8 and -9 and TIMP-2 concentrations were higher at TB diagnosis in patients who remain sputum culture positive at
2 weeks and MMP-3, -8 and TIMP-1 concentrations were higher in these patients at 2nd week of TB treatment.
Conclusions: MMPs are elevated in TB patients and associate with disease severity. This matrix-degrading phenotype
resolves rapidly with treatment. The MMP profile at presentation correlates with a delayed treatment response.
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Introduction
Tuberculosis (TB) remains a global pandemic, with around 8.7
million new cases in 2011 [1]. Multi and extensively drug resistant
TB is increasing world-wide and although some new drugs are
emerging [2], new approaches to therapy are required which
depend on improved understanding of pathophysiology. In
patients with active pulmonary disease, there is lung tissue
damage, most characteristically with cavitation [3]. Such tissue
damage facilitates spread of M. tuberculosis (Mtb). Lung tissue
destruction is in part a consequence of Matrix Metalloproteinase
(MMP) activity [4]. MMPs are zinc-dependent proteases which
collectively can degrade all components of the extracellular matrix
and are involved in remodelling and repair of diverse tissues
[5,6,7]. Increased MMP activity is associated with inflammation in
diverse infections [8,9,10] as well as in non-infective pulmonary
diseases such as asthma and COPD [11].
We and others have demonstrated that MMPs are key in
destruction of the lung interstitial matrix in TB and may have a
role in regulating leukocyte migration to the granuloma [4,12].
Mtb may drive MMP-1, -3, -7 and -9 secretion from monocytes,
macrophages or pulmonary epithelial cells, suggesting that
multiple proteases may contribute to pathology in TB
[13,14,15,16]. Relatively few small, focused clinical studies have
demonstrated increased MMP concentrations in TB patients
usually with minimal analysis of clinical data [4,17]. Furthermore,
no longitudinal investigation of changes in secretion of MMPs and
their specific Tissue Inhibitors of Metalloproteinases (TIMPs)
during TB treatment has been performed. In addition, the
relationship between time to culture conversion on TB treatment
and MMP activity is unknown.
In this study, we first compared induced sputum MMP and
TIMP concentrations in TB patients with healthy controls in a
prospectively recruited, carefully clinically characterised cohort of
HIV negative patients. Next, we investigated alterations in sputum
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MMP and TIMP concentrations during the 6 months treatment
period and their relation to sputum culture conversion.
Methods
Study design
First, a cross-sectional evaluation of TB patients and controls
was performed. Next, from these TB patients, a longitudinal,
prospective follow-up was performed during the standard 6-month
period of treatment for TB.
Population recruitment
The recruitment occurred between August 2009 to November
2010. . Study participants were recruited in health centres in
Lima. Inclusion criteria for TB participants were: microbiologi-
cally confirmed diagnosis of TB (positive sputum smear micros-
copy and/or positive TB culture), age $18 years, cough with
sputum production and no prior history of TB or TB treatment.
Controls were recruited among the relatives who were
accompanying pregnant women or children for routine medical
visits and/or accompanying patients with non-related TB disease.
The inclusion criteria for controls were: over 18 years of age, had
no symptoms associated with TB (cough for more than 14 days,
night sweating and weight loss), no known TB contact, a normal
chest radiograph and negative sputum TB culture.
Exclusion criteria for both groups were immunological com-
promise including HIV infection and current treatment with
corticosteroids and/or any other immunomodulatory drugs, as
well as any conditions where sputum induction is contra-indicated
including asthma, chronic obstructive pulmonary disease or
oxygen saturations ,94%. Any form of drug resistant TB also
excluded a patient from the study.
Field Study procedures
Eligible patients gave informed consent and underwent a
clinical and epidemiological evaluation. To evaluate the severity of
the disease, we used the TBscore [18]. TBscore is a simple clinical
evaluation score used for clinical monitoring of TB patients in low-
resource settings, which may be used to predict mortality risk.
Mortality and disease severity are increased in patients with a
TBscore greater than 8. In addition, digital chests X-rays (CXR)
were obtained and were scored for degree of pulmonary
infiltration using ImageJ analysis [17]. Blood was taken for HIV
ELISA testing. Follow-up evaluation of TB patients was performed
at 2, 8 and 24 weeks (at the end of therapy) after starting TB
treatment and at each time point, an induced sputum sample was
taken and the TBscore re-evaluated.
Sputum induction was performed to obtain consistent samples
from the bronchial tree. The procedure for sputum induction (SI)
was in a designated sputum collection cabin, situated outside of the
main clinical facility with an open roof and good ventilation. Staff
infection control protection measures included use of appropriate
respiratory protection masks (N95) and minimizing the time spent
in the room during the procedure. For each SI procedure, 30 mL
of 3% hypertonic saline was administered via a mouthpiece using
a nebulizer NA180 (Aspen, Buenos Aires, Argentina). Participants
were encouraged to expectorate and the procedure was discon-
tinued after 3 ml of sputum has been obtained.
Induced sputum processing
SI samples were transported at 4uC to the TB containment
level-3 research laboratory at Universidad Peruana Cayetano
Heredia (Lima, Peru). One aliquot was used for auramine smear
microscopy and mycobacterial culture/direct drug susceptibility
testing by the MODS method [19]. The remaining sample was
centrifuged at 430 g to remove cellular debris, and then the
supernatant was filtered through a 0.2 mM Durapore membrane
(Millipore, Billerica, MA, USA). This protocol does not remove
MMPs [20]. Samples were aliquoted and frozen at220C analysed
for MMP activity.
Concentrations of MMP-1, -2, -3, -7, -8, -9 were analysed by
Luminex multiplex array (R&D Systems, Minneapolis, MN,
USA). TIMP-1 and TIMP-2 were analyzed by ELISA kit (R&D
Systems, Minneapolis, MN, USA). Total protein concentration
was measured by Bradford assay [21] (Sigma-Aldrich, St Louis,
MO, USA).
Statistical analysis
Statistical analyses were performed using PRISM Version 5
(GraphPad, La Jolla, CA, US) and STATA 12 (Stata Corp.,
College Station, TX, USA). Parametric data are presented as
mean and standard deviation (SD) and nonparametric data as
median and interquartile range (IQR). Analysis between groups
was by unpaired t test for parametric data and by Mann-Whitney
U test for non-parametric data. Ordered logistic regression was
used to evaluate association between TB Score and MMP
concentrations. Correlation between MMPs was assessed by
Spearman analysis. The non-parametric Friedman test and
Dunn’s multiple comparison post hoc test was used to compare
differences between visits [22]. A p,0.05 was considered
significant.
Ethics Statement
This study received Institutional Review Board approval from
Universidad Peruana Cayetano Heredia, Lima, Peru and the
Peruvian Ministry of Health (DISA Lima Este). Written informed
consent was received from all participants and all data was
processed anonymously.
Results
Cross Sectional Study
We enrolled 68 TB participants and 69 healthy controls. The
demographic and clinical characteristics are presented in Table 1.
All patients had drug-sensitive TB. There were more males in the
TB patient group than in the control group but gender was not
significantly associated with MMP or TIMP concentrations overall
or within groups when analysed by Mann-Whitney test. MMP-1, -
2, -3, -8, and -9 concentrations were increased in TB patients
compared to controls as were TIMP-1/2 concentrations (p,0.001
for each variable; Figure 1 and Figure 2). MMP-7 was no different
between TB patients and control subjects. In TB patients, sputum
MMP-3 and -9 concentrations were increased 15.2 fold and 14.4
fold respectively which were the greatest fold increases compared
to controls. We investigated correlations between MMPs and
TIMPS, and demonstrated correlations between the gelatinases
MMP-2 and -9 (Rho=0.83; p,0.001), between MMP-1 and its
activator MMP-3 (Rho=0.64; p,0.001). TIMP-1 concentrations
correlated with MMP-8 (Rho= 0.71; p,0.001) and TIMP-2
concentrations with TIMP-1 (Rho= 0.74; p,0.001), MMP-2
(Rho= 0.66; p,0.001), -8 (Rho= 0.82; p,0.001) and -9
(Rho= 0.61; p,0.001).
Next, we analysed the relationship between clinical character-
istics and sputum MMP concentrations. MMP-3 concentrations
were elevated in patients with cough or with positive findings on
auscultation, which may result from pulmonary inflammation
(p = 0.02 and 0.01 respectively; Figure 3A/B).. MMP-8 concen-
trations were increased in TB patients with night sweats (p = 0.01,
Sputum MMPs Concentrations during TB Treatment
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Figure 3C). There was no statistically significant difference in
MMPs and TIMPs concentrations in patients who had dyspnoea,
chest pain or haemoptysis compared to those who did not. MMP
and TIMP concentrations did not correlate with body mass index
(BMI), temperature or age. MMP-3 had the best correlation with
CXR score (Rho= 0.63; p,0.01).
To investigate the relationship of MMP/TIMP concentrations
with the clinical disease severity score, we developed an ordered
logistic regression model. The TB Score was categorized in 3 equal
Figure 1. Multiple MMP concentrations are increased in induced sputum from TB patients. MMP-1, MMP-2, MMP-3, MMP-8, MMP-9
concentrations are significantly increased among TB patients compared to healthy controls analysed at time of TB diagnosis. The horizontal line is the
median value.
doi:10.1371/journal.pone.0061333.g001
Figure 2. TIMP-1/2 concentrations are elevated in TB patients compared to controls. TIMP-1 and TIMP-2 concentrations are increased in
induced sputum from TB patients compared to healthy controls analysed at time of TB diagnosis. The horizontal line is the median value.
doi:10.1371/journal.pone.0061333.g002
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percentiles (#5; .5 and ,7; $7). Univariate analysis showed no
association between MMP or TIMP concentrations with TB
Score. In the multivariate analysis, after adjustment for age,
gender, MMPs and TIMPs, MMP-1 and -3 were independently
associated with TB Score (p,0.05).
Longitudinal Cohort Study
From the 68 patients with TB, 46 were followed-up longitudi-
nally during the course of treatment until cure. There were no
statistically significant differences in baseline characteristics
between cross-sectional and cohort TB patients. Fifty-seven
percent of patients were culture negative at the first follow-up
visit at 2 weeks and 100% by the 8-week review, and all remained
culture negative until the end of treatment. Median (IQR) TB
Scores at enrolment, 2nd, 8th and 24th weeks were 5(6), 3(4), 1(2)
and 0(1) respectively showing clinical improvement (Figure 4).
MMP concentrations decreased during TB treatment (Figure 5).
MMP-1, MMP-3 and MMP-8 concentrations were significantly
different at 2nd, 8th and 24th weeks compared with baseline
Table 1. Characteristics of the study population.
Characteristics Healthy Participants (n=69)
Tuberculosis Participants
(n=68) P-value (*)
Male (%) 12 (17.4%) 42 (61.8%) ,0.001
Mean Age (SD) 32.7 (12.6) 31.1 (13.8) NS
Mean BMI (SD) 25.6 (3.8) 21.0 (2.9) ,0.001
Mean Temperature (SD) 36.2 (0.2) 36.6 (0.6) ,0.001
Mean TBscore (SD) 0.2 (0.4) 5.6 (1.9) ,0.001
Cough (%) 1 (1.5%) 63 (92.7%) ,0.001
Haemoptysis (%) 0 (0%) 30 (44.1%) ,0.001
Dyspnoea (%) 0 (0%) 37 (54.4%) ,0.001
Chest pain (%) 0 (0%) 36 (52.9%) ,0.001
Night sweating (%) 0 (0%) 42 (61.8%) ,0.001
Pale conjunctivae (%) 5 (7.3%) 61 (89.7%) ,0.001
Tachycardia (%) 1 (1.5%) 20 (29.4%) ,0.001
Abnormal lung examination (%) 2 (2.9%) 61 (89.7%) ,0.001
Axillary Temperature .37 C 0 (0%) 9 (13.2%) 0.002
Body mass index (BMI) 0.01
BMI,18 0 (0%) 5 (7.35%)
BMI,16 0 (0%) 3 (4.4%)
Middle upper arm circumference (MUAC) 0.05
MUAC ,22 cm 3 (4.4%) 8 (11.8%)
MUAC ,20 cm 0 (0%) 3 (4.4%)
*T test for differences of means; X2 for difference in proportions.
TBscore is drive all clinical and anthropometric data presented in the table.
NS = not significant.
doi:10.1371/journal.pone.0061333.t001
Figure 3. Clinical characteristics and their correlation with MMP-3 and -8 concentrations. MMP-3 concentrations are increased among TB
patients who presented with (A) cough and (B) positive findings on auscultation. (C) MMP-8 concentrations are increased among TB patients who
reported night sweats.
doi:10.1371/journal.pone.0061333.g003
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(p,0.001). The decrease in MMP-2 and MMP-3 concentrations
between 2 and 24 weeks was significant (p,0.001). In contrast,
TIMP-1 and -2 concentrations were significantly increased at 2
and 8 weeks compared to concentrations at the start of TB therapy
(p,0.05). TIMP-2 concentrations at 24th week were significantly
increased compared with baseline (p,0.001). TIMP concentra-
tions decreased after 2nd week, but did not fall below values at the
enrolment visit (Figure 6).
MMPs and TB culture conversion
Next, we analysed patients according to whether they became
sputum culture negative at 2 weeks or not (culture conversion).
Culture conversion was not related to TBscore at baseline
(Figure 7A). MMP-2, MMP-8, MMP-9 and TIMP-2 concentra-
tions at beginning of TB treatment were significantly higher
among patients who remained culture positive at 2nd week
(p,0.01 Figure 7B–E). At week 2, MMP-3, MMP-8 and TIMP-
1 concentrations remained higher amongst those who were culture
positive compared with culture negative patients (p,0.05;
Figure 7F–H).
Discussion
In this first longitudinal analysis of a carefully characterised
cohort of TB patients, we demonstrate that multiple MMP and
TIMP concentrations are increased in TB patients at presentation,
and that MMP-1 and -3 correlated most closely with the TB
severity. As patients clinically improve, MMP-1, -3, and -8
concentrations decrease rapidly during treatment. In contrast,
TIMP-1/2 concentrations increase, indicating some resolution of
the matrix-degrading phenotype in which increased MMP activity
is relatively unopposed by TIMPs [23].
In this patient population, MMP-1, -2, -3, -8 and -9
concentrations as well as TIMP-1/2 concentrations were markedly
elevated in TB patients. These data are consistent with previous
Figure 4. Median TBscore falls in patients over the course of
the study. There is a significant decrease of TBscore comparing 2nd, 8th
and 24th weeks with enrolment (p,0.05).
doi:10.1371/journal.pone.0061333.g004
Figure 5. Sputum MMP concentrations decrease during TB treatment. 46 patients were followed longitudinally and induced sputum was
collected at enrolment, weeks 2, 8 (at the end of the intensive treatment phase) and at the end of treatment (24 weeks). MMP-1, -2, -3, -8 and -9
concentrations significantly decreased during the course of treatment.
doi:10.1371/journal.pone.0061333.g005
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findings from ourselves and others [4,17,24] although the key role
of MMP-8 which is secreted by diverse cells including neutrophils,
increasingly recognised as a key cell in the immune response to TB
[25,26], has not been previously defined. Immunoreactive MMP
concentrations were analyzed by Luminex array, and we have
previously shown that this corresponds to MMP activity analyzed
by casein zymography [4]. MMP-1 and -3 concentrations were
correlated most consistently with clinical findings including overall
TB score and may reflect the extent of pulmonary tissue
destruction. Although MMP-9 concentrations were significantly
elevated in patients with TB, there was significant overlap and
some patients had levels equivalent to controls, which may reflect
biological variability in airway MMP concentrations.. MMPs with
similar functions such as the gelatinases MMP-2 and -9 correlated
closely, as did the stromelysin MMP-3 with the collagenase MMP-
1, which may form part of a proteolytic cascade [27]. TIMP
Figure 6. TIMP concentrations initially rise during TB treatment. In contrast to the decline in MMP concentrations, TIMP-1 and TIMP-2
concentrations significantly increase in the first two weeks of treatment, indicating a switch from a matrix degrading to matrix protective
environment. Subsequently TIMP-1/2 concentrations decrease.
doi:10.1371/journal.pone.0061333.g006
Figure 7. MMP and TIMP concentrations at admission and 2 weeks into therapy correlate with sputum culture conversion at 2
weeks. (A) TBScore is not significantly different at baseline between sputum converters and non-converters. MMP-2, MMP-8 and MMP-9 and TIMP-2
(B–E) concentrations at diagnosis are higher in patients who remain culture positive at 2 weeks (shaded boxes) than those who culture convert (open
boxes). At 2 weeks of treatment, MMP-3, MMP-8 and TIMP-1 (F–H) concentrations are elevated in patients who remain culture positive compared to
those who are culture negative. Boxes indicate 25 and 75 centile with median value; whiskers are 10–90 centiles. (*) p,0.05 (**) p,0.01 and (***)
p,0.001.
doi:10.1371/journal.pone.0061333.g007
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concentrations also correlate with various MMPs but whether this
is because they are co-secreted is unknown.
The longitudinal study has revealed that as patients respond to
treatment, MMP-1, -3 and -8 concentrations fall rapidly within 2
weeks although all MMP concentrations continued to further
decrease over the study period. However, even at the end of TB
treatment, MMP concentrations remain elevated, which is
consistent with data on pro-inflammatory chemokines [28].
Together with the elevated TIMP-1/2 concentrations observed
at 6 months, this may indicate that tissue remodelling continues
which may be one reason that some patients develop fibrotic lung
disease following infection.
An interesting observation was the increase in TIMP-1/2
concentrations 2 weeks into TB treatment. We have previously
proposed that active TB is characterised by a matrix degrading
phenotype [8,29] in which MMP activity is relatively unopposed
by inhibitors. It may be that early in the resolution phase of acute
TB a rise in TIMP secretion matched by a fall in MMP release is
the host response to reverse the matrix degrading phenotype. This
increase in TIMPs with a concurrent suppression of MMPs may
help preserve lung matrix and facilitate the remodeling of the lung
after the extensive destruction driven by pulmonary TB.
The TBscore at the start of treatment did not differ between
patients who subsequently become TB sputum culture negative or
not. However, those patients who remain culture positive at 2nd
week had higher sputum concentrations of MMP-2, -8 and -9 at
baseline and of MMP-3, -8 and -9 at 2nd week. TIMP-2 was
similarly elevated. This may suggest that increased sputum TB
load is associated with increased tissue destruction. Possibly these
mediators may be useful components of a biomarker panel for
active TB [30] or MMPs may be predictors of poor response to
treatment. In order to more fully explore this, further studies of
MDR-TB patients and others not responding to treatment is
required.
In conclusion, MMPs particularly MMP-1 and its activator
MMP-3 are elevated in patients with TB and relate to clinical
symptoms. MMP-1, -3 and -8 concentrations fall sharply with
treatment and at the same time there is an associated increase in
inhibitor TIMP concentrations, which may reflect resolution of the
matrix degrading phenotype. At the end of successful therapy,
MMP and TIMP activity remains elevated, which may be key in
tissue remodelling and scarring that lead to long-term fibrosis. The
data suggest an unrecognized role for MMP-8 that is persistently
elevated and high concentrations are associated with more
persistent sputum positivity. It is not clear whether this reflects
neutrophil activity in TB and further data are also required to
determine its role in tissue destruction. Our results suggest that
specific MMPs may be a useful component of a biomarker panel
for active TB with other clinical and immunological parameters.
Further longitudinal studies as well as work in cellular and animal
models exploring MMP activity in non-healing and drug-resistant
disease will elucidate whether MMPs or their upstream regulators
are potential therapeutic targets.
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